• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified

byRishi ChopraandDavid Wang
May 15, 2017
in Gastroenterology, Imaging and Intervention, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In a retrospective study of 111 patients with hepatocellular carcinoma (HCC) with extrahepatic spread (EHS) treated with transarterial chemoembolization (TACE), median overall survival was 3.8 months.

2. Maximum tumor size ≥10 cm, the presence of multifocal intrahepatic tumors, and portal vein tumor thrombosis were elucidated as indicators of poor prognosis.

Evidence Rating Level: 3 (Average)   

Study Rundown: Advanced HCC is associated with poor outcomes and median overall survival of 6 to 20 months. In HCC patients with EHS, previous studies have demonstrated that intrahepatic tumor burden is a poor prognostic indicator for disease progression and overall patient survival. Thus, treatments such as TACE, which specifically target intrahepatic lesions, may improve survival. The objective of the present study was to evaluate treatment outcomes of TACE in patients with HCC and EHS and to establish prognostic factors to select the optimal candidates for treatment.

This study retrospective evaluated the use of TACE with doxorubicin in 111 patients with HCC and EHS. At the conclusion of the study, the median overall survival was 3.8 months. Maximum tumor size ≥10 cm, the presence of multifocal intrahepatic tumors, and portal vein tumor thrombosis (PVTT), were elucidated as indicators of poor prognosis. These findings demonstrate that TACE is most likely not an optimal therapy in this subset of patients, but may benefit patients with lower intrahepatic tumor burden. Strengths of this study include the exclusion of patients who were undergoing other simultaneous therapies. However, limitations include the study’s retrospective nature, short-term follow-up duration, and lack of control group for comparison. Larger, prospective, multicenter trials that compare TACE to sorafenib may provide more robust conclusions.

Click to read the study in JVIR

Relevant Reading: Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors

RELATED REPORTS

Non-alcoholic fatty liver disease-related hepatocellular carcinoma (HCC) differ clinically compared to HCC due to other causes

Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma

2 Minute Medicine Rewind December 24, 2018

In-Depth [retrospective cohort]: This study retrospectively evaluated TACE with doxorubicin in 111 patients with HCC and EHS at a single center in China. Patients were diagnosed according to the criteria of the European Association for the Study of Liver Disease and American Association for the Study of Liver Disease guidelines, and EHS was determined using imaging and/or pathology. Median overall survival was 3.8 months (95%CI: 2.9–4.7 months). Multivariate analysis demonstrated that maximum tumor size ≥10 cm (HR 1.58; 95%CI: 1.02 to 2.46; p = 0.041), intrahepatic tumor distribution (HR 1.55; 95%CI: 1.03 to 2.33; p = 0.037), and PVTT (HR 1.81; 95%CI: 1.12 to 2.91; p = 0.015) were poor prognostic factors. Intrahepatic tumor size ≥10 cm was associated with significantly shorter overall survival compared to <10 cm (2.6 months vs. 6.0 months, p < 0.001).

Image: CC/Wiki/Ed Uthman

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hepatocellular carcinoma (HCC)transarterial chemoembolization (TACE)
Previous Post

Long-term use of apremilast for psoriasis associated with an acceptable safety profile

Next Post

United States sudden unexpected infant death rates vary by race/ethnicity  

RelatedReports

Patient Basics: Liver Cancer
Oncology

Non-alcoholic fatty liver disease-related hepatocellular carcinoma (HCC) differ clinically compared to HCC due to other causes

March 14, 2022
Resection of colorectal liver metastases may improve cost and longevity
Oncology

Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma

December 21, 2021
Prognostic indicators for transarterial chemoembolization in patients with hepatocellular carcinoma with extrahepatic spread identified
Weekly Rewinds

2 Minute Medicine Rewind December 24, 2018

December 26, 2018
Next Post
Physician gaps in maternal infant care counseling

United States sudden unexpected infant death rates vary by race/ethnicity  

ACP releases practice guidelines for the evaluation of suspected acute pulmonary embolism

2 Minute Medicine Rewind May 15, 2017

African American and Hispanic youth more likely to discontinue ADHD treatment

African American and Hispanic youth more likely to discontinue ADHD treatment

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.